Watch LFST. Know when insiders buy.
One email the day a filing lands. Free.
Work order
20
FLAG · insiders 30, shorts 9
Insiders, 90 days
−$541K
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $4.9BP/E —DIV YIELD —FCF YIELD 3.58%REV TTM $1.6B +20.4%NET INCOME $50.6MNET DEBT $49.6M52W 4.81 – 12.89SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $435.4M | +26.1% | — | $30.7M | $23.6M | — | — | $99.9M | $12M | $87.9M | Aug 6 |
| Q1 2026 · Mar 31 | $403.5M | +21.2% | — | $22.3M | $14.2M | +1908.9% | — | $33.1M | $10.8M | $22.3M | May 7 |
| Q4 2025 · Dec 31derived | $382.2M | +17.4% | — | $18.1M | $11.7M | — | — | $57.6M | $10.9M | $46.6M | Feb 25 |
| Q3 2025 · Sep 30 | $363.8M | +16.3% | — | $7.4M | $1.1M | +51.9% | — | $27.3M | $10.3M | $17M | Nov 6 |
| Q2 2025 · Jun 30 | $345.3M | +10.6% | — | −$3M | −$3.8M | — | — | $64.4M | $7.8M | $56.6M | Aug 6 |
| Q1 2025 · Mar 31 | $333M | +10.8% | — | $1.6M | $709K | — | — | −$3.1M | $7.2M | −$10.3M | May 7 |
| Q4 2024 · Dec 31derived | $325.5M | +16.0% | — | $1.1M | −$7.1M | — | — | $62.3M | $6.3M | $56M | Feb 25 |
| Q3 2024 · Sep 30 | $312.7M | +19.0% | — | $47K | $709K | — | — | $22.7M | $5.1M | $17.7M | May 7 |
| Q2 2024 · Jun 30 | $312.3M | — | — | −$15.9M | −$23.3M | — | — | $44.1M | $5.1M | $39M | Aug 7 |
| Q1 2024 · Mar 31 | $300.4M | — | — | −$16.8M | −$21.1M | — | — | −$21.8M | $5.1M | −$26.9M | May 7 |
| Q4 2023 · Dec 31derived | $280.6M | — | — | −$32.3M | −$45M | — | — | $16.8M | $11.4M | $5.4M | Feb 25 |
| Q3 2023 · Sep 30 | $262.9M | — | — | −$74.4M | −$61.6M | — | — | −$25.4M | $9.8M | −$35.2M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $1.4B | — | $24.1M | $9.7M | 0.7% | — | $146.2M | $36.1M | $110M | — | — |
| FY2024 · to Dec 31 | $1.3B | — | −$31.6M | −$57.4M | -4.6% | — | $107.3M | $21.6M | $85.7M | — | — |
| FY2023 · to Dec 31 | $1.1B | — | −$189.1M | −$186.3M | -17.6% | — | −$16.9M | $40.5M | −$57.4M | — | — |
| FY2022 · to Dec 31 | $859.5M | — | −$210.2M | −$215.6M | -25.1% | — | $52.8M | $79.3M | −$26.5M | — | — |
| FY2021 · to Dec 31 | $667.5M | — | −$286.4M | −$307.2M | -46.0% | — | $9.4M | $94.5M | −$85.1M | — | — |
| FY2019 · to Dec 31 | $212.5M | — | $15.2M | $5.7M | 2.7% | — | $17M | $14.3M | $2.7M | — | — |
Every number comes from LifeStance Health Group, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.